

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after Final Rejection. Since this application is eligible for continued Examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office Action has been withdrawn pursuant to 37 CFR 1.114.

Applicant's submission filed on 02/28/2008 has been entered.

2. Claims 1-36 have been canceled.

Claims 37-45 are pending.

EXAMINER'S AMENDMENT

3. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Harold Wells on 03/06/2008.

4. See attached for Amendment to the Claims.
5. The title has been replaced with the following:
-- MONOCLONAL ANTIBODIES FOR DETECTION OF URINARY TRYPSIN INHIBITORS --

REASONS FOR ALLOWANCE

6. The following is an examiner's statement of reasons for allowance:

Applicant's amendment to the claims and Applicant's argument distinguishing the instant monoclonal antibodies from prior art, filed 02/28/2008, in conjunction with the Examiner's Amendment in this Office Action have obviated previous rejections under 35 U.S.C. 112 first and second paragraphs and 35 U.S.C. 102(b) and have placed this application in condition for allowance. The instant method of assaying for urinary trypsin inhibitor using the monoclonal antibodies recited in the claims appear to be free of the prior art. Accordingly the instant claims are deemed allowable.

7. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHARON WEN whose telephone number is (571)270-3064. The examiner can normally be reached on Monday-Thursday, 8:30AM-6:00PM, ALT. Friday, EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eileen O'Hara can be reached on (571)272-0878. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Sharon Wen, Ph.D./
Examiner, Art Unit 1644
March 20, 2008

/Phillip Gambel/
Phillip Gambel, Ph.D., J.D.
Primary Examiner
Art Unit 1644
03/20/2008